GenomePrecision Technology of Beijing completed a $15 million B round, led by Yizhuang Biomedical M&A Fund. A six-year-old company, GenomePrecision develops molecular diagnostic products including precision medicine tests. Its operations include R&D, manufacturing, distribution, registration and services. The company has developed multiple series of tests for leukemia, lymphoma, transplant typing, solid tumor detection, pharmacogenomics, pathogen detection, cervical cancer products and research use. More details....
Share this with colleagues:
Original Article: Beijing GenomePrecision Raises $15 Million for Molecular Diagnostics